Sight Diagnostics
Yoav joined Sight to build and lead its finance team. Prior to joining Sight, Yoav worked at Neuroderm (NASDAQ: NDRM) and had a pivotal role in two follow-on public offerings on Nasdaq and NDRM's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for $1.1 billion.
As a CPA, Yoav holds a B.A. in Accounting and Economics from Ben Gurion University and currently lectures several courses in the Accounting Department at Ben Gurion University.
This person is not in any offices
Sight Diagnostics
The faster we diagnose, the faster we can treat. At Sight Diagnostics, we aim to improve health through fast, accurate and convenient diagnostic testing. Sight’s latest analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes, not hours. It’s compact: designed to be used by anyone, anywhere. Sight’s method, developed over a decade of research, represents a step-change in diagnostic technology. Our analyzers create a digital version of your blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by our proprietary algorithms. Sight’s first product was focused on detecting Malaria, used in 24 countries, and has delivered almost 1 million tests to date. At Sight, exceptional individuals work together to achieve extraordinary things. We have rapidly growing offices in London, New York, and Tel Aviv.